On Sept. 2, 2020, the Janssen Pharmaceutical Companies of Johnson & Johnson announced that it had made a strategic decision to discontinue the development of pimodivir, an investigational antiviraltreatment for influenza A infection.

This decision was based on results from pre-planned interim analyses of the pimodivir Phase 3 trialin hospitalized patients with influenza A, that found pimodivir in combination with the standard of care (SOC) was very unlikely to demonstrate added benefit in hospitalized patients with influenza A compared to SOC treatment alone.